Alembic Pharmaceuticals Limited Investor Presentation September 2012 BSE: Symbol: ALEMPHARM Code: 533573 NSE: Symbol: APLLTD ISIN: INE901L01018 www.alembic-india.com
Safe Harbour Statement Materials and information provided during this presentation may contain ‘forward - looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include general industry and market conditions and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited, to technological advances and patents attained by competitors, challenges inherent in new product development including completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trend towards managed care and healthcare cost containment and governmental laws and regulations affecting domestic and foreign operations. Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited, to inability to build production capacity to meet demand, unavailability of raw materials and failure to gain market acceptance.
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
The Alembic Journey 2003 State-of-the-art 2001 Formulations facility for Starts Regulatory 1972 manufacturing Markets of "Althrocin"- a Cephalosporin C 1971 brand of Erythromycin Erythromycin launched 1961 manufactured for the first Lal Bahadur time in India 1940 Shastri, the then Started Prime minister 1907 manufacturing inaugurates the cough syrup, Penicillin plant Started vitamins, tonics manufacturing and sculpture tinctures and drugs alcohol at Vadodara
The Alembic Journey 2012 - Para IV filed 2011 - Cumulatively 50 ANDAs filed, - ANVISA (21 approved) 2010 approvals and 66 DMFs filed - Aggressive - Azithral sales ANDAs and 2009 Reach INR DMFs filing 1000 million Addressed mark 2007 chronic therapies - Demerger AL-APL through Acquisition of multiple 2006 Non-Oncology marketing Business of divisions US FDA M/s Dabur 2004 approvals for Pharma Ltd. API and State-of-the-art Formulation Research Plants Centre established in Vadodara
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Insight - Alembic Overview Branded Formulations Revenue of INR 7830 million Ranked 22nd in the Ranked 15th in Well equipped in the domestic market for Indian Formulations Doctors Prescription Formulations Plant the financial year 2011-12 market with a market Universe** located at Baddi, share of 1.74%* Himachal Pradesh Dermatology division Robust product basket Strong presence in Thrust on Cardiology, with export sales of Gynecology, GI, launched anti-infective, INR 570 million in the financial pain management, Diabetes, Orthopedics, year 2011-12 in International cough & cold Rheumatology and Branded Formulations Ophthalmology segments *Source: ORG August, 2012 **Source: ORG Prescription Audit
Insight - Alembic Overview International Division Business size of Sales in Regulatory 1 US FDA World-class INR 6290 million in the Generics Market of INR 2550 approved R&D and F&D financial year 2011-12 million in the financial year Formulations facility Plant 2011-12 Alliances with leading Robust product basket Approved 3 US FDA generic players in USA, with 21 ANDA approvals approved Bio Equivalence Canada, Europe, Australia, (50 filings) and 66 DMFs. API Plants Centre Brazil and South Africa and Para IV filing
Business Portfolio R&D BRANDED Alliances API Quality FORMULATIONS Business Synergies INTERNATIONAL Manufacturing GENERICS Efficiency
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Strategic Advantage Alembic Research Centre is Well-developed the first in India to be Infrastructure facility - Information Security Certified 4 US FDA approved plants High-end quality / Highly talented pool of RA structure 300 Research Scientists Manufacturing excellence R&D / F&D / Captive with optimal cost benefits Bio-equivalence facility Long term Therapy focused marketing Therapy focused marketing Strong partnership through 12 marketing arms through over 3,600 field force and alliance relationship with on PAN India basis covering over 1 lac doctors in Generic space API customers
Manufacturing Infrastructure Formulations - Generics API Branded Formulations (Regulatory Markets) USFDA, MCC, MHRA, Formulations plant at USFDA, EDQM, TGA, WHO ANVISA, TPD approved Baddi, Himachal Pradesh approved API facility at formulations facility at Panelav Panelav (2 units) and at Karkhadi (1 unit) Current annual production capacity of 2.6 billion tablets/capsules Expansion to 4 billion in financial year 2012-13
Manufacturing Infrastructure Certifications
Alembic Research Centre State-of-the-art Analytical & IPR infrastructure R&D FACILITY F&D CAPABILITIES BIO EQUIVALENCE CENTRE R&D Centre has been Expertise in Drug Deliveries State-of-the-art 90-bedded new recognized by DSIR, and Niche Formulations Bio Centre Govt. of India Well-defined Processes 100 Bio Pilot Studies High-end R&D Equipment - and Quality Systems NMR XRD, TGA, DSC, LCMS Capabilities in Solid Oral, 25 Pivotal Studies (Capabilities) World-class Infrastructure Liquid Oral Products
Research Capabilities 50 66 ANDA Filing ANDAs filed DMFs filed with DMFs Filing 21 approvals 74 74 in place 55 55 62 62 45 45 53 53 38 38 39 39 28 28 28 28 17 17 19 19 11 11 17 17 14 14 12 12 11 11 11 11 11 11 10 10 10 10 9 9 8 7 Up to 2008 08-09 09 2009-10 10 2010-11 11 2011-12 12 Expe pecte ted Up to 2008-09 09 2009-10 10 2010-11 11 2011-12 12 Expe pecte ted 2007 2007-08 08 2012-13 13 2007 07-08 08 2012-13 13
Global Presence 21 ANDA Approvals: Pramipexole Dihydrochloride Tablets Lamotrigine Tablets Famotidine Tablets USP Losartan Potassium Tablets (Para IV) Venlafaxine Hydrochloride Tablets Irbesartan Tablets USP (Para IV) USA / Lithium Carbonate Capsules USP Hydrochlorothiazide Capsules CANADA Metronidazole Tablets USP Clonidine Hydrochloride Tablets USP Generics Metronidazole Capsules Leflunomide Tablets USP Meprobamate Tablets USP Irbesartan and Hydrochlorothiazide Tablets USP Metronidazole ER Tablets Losartan Potassium-Hydrochlorothiazide Tablets Rivastigmine Tartrate Capsules Fluoxetine Capsules USP Modafinil Tablets USP Ropinirole Hydrochloride Tablets Theophylline Extended - Release Tablets Working on complex EUROPE generics products Generics Filings from Indian site Map not to scale
Effective Marketing PAN India Marketing and Distribution Network OSTEOFIT ZENOVI Orthopedics Gynecology SPECIA Cardiology Diabetes SUMMIT Urology EYECARE INTENSA ENTERON Cardiology Ophthalmology Critical Care Gastrology Diabetes ALCARE MAXIS Rural OTC & Focused General SPECIALITY PHARMA MEGACARE MARKETING General Acute General Acute DIVISION Division Division Future Segment: Respiratory therapies New Segment entered: Dermatology
Effective Marketing PAN India Marketing and Distribution Network VETERINARY GENERICS & NSA OTHER PRODUCT PORTFOLIO
Major Product Portfolio Top Therapatic Ranking Other Therapatic * Products Area Products Area Ulgel Antacid and Anti Flatulant Azithral Anti Infective 26 Zeet/Bro-Zeet Cough & Cold Althrocin 44 Anti Infective Tellzy Cardiology Roxid Anti Infective 126 Gestofit Gynecology Sharkoferrol Tonic Wikoryl 144 Cough & Cold Tetan Cardiology Livfit Hepaprotectives Zofix Anti Infective Revas Cardiology Glisen Anti Diabetic Glycodin Cough & Cold * Source: ORG August, 2012
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Growth Drivers Branded Formulation Business International Generic Business CAGR CAGR INR million INR million 16% 37 % 58% 9 % 7830 7830 2550 2550 6930 6930 1890 1890 5840 5840 1020 1020 2009 2009-10 10 2010-11 11 2011-12 12 2009 2009-10 10 2010 10-11 11 2011-12 12
Growth Drivers Branded Formulations Enhanced focus on existing branded business Expected Through effective pan-India distribution annual growth network and therapy based marketing and by pushing ahead acute and chronic 15% segments like anti-infectives and cough & cold medications Launch 20-25 new products Launch of new products to boost sales momentum and brand build up
Recommend
More recommend
